Dr. Adewuyi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
743 Spring St NE
Gainesville, GA 30501
Education & Training
Northeast Georgia Medical CenterResidency, Internal Medicine, 2023
Ross University School of MedicineClass of 2022, MD- Touro College of Osteopathic MedicineMS, Interdisciplinary Studies, 2016 - 2017
- University of Maryland BaltimoreMS, Molecular Medicine , 2014 - 2016
- Towson University BS, Biochemistry & Molecular Biology , 2010 - 2012
- Prince George's Community CollegeAA, Biology, Chemistry, Pre-Med, 2007 - 2010
Awards, Honors, & Recognition
- CoSMiC Scholar Award Towson University, 2011
- TriBeta Honors Towson University, 2011
- Tutor of the Year Prince George's Community College, 2010
- Join now to see all
Publications & Presentations
PubMed
- 57 citationsHistone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatinCarine Robert, Pratik K. Nagaria, Nisha R. Pawar, Adeoluwa Adewuyi, Ivana Gojo
Leukemia Research. 2016-06-01
Journal Articles
- An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancer Independent of BRCA Mutations. Nicholas Pulliam, Fang Fang, Ali R. Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B. Baylin, Daniela Matei, Harikrishna Nakshatri, Feyruz V...., Clinical Cancer Research, 7/1/2018
- Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARPR1 at DNA double-strand breaks in chromatin. Carine Robert, Pratik K Nagaria, Nisha Pawar, Adeoluwa Adewuyi, Ivana Gojo, David J Meyers, Philip A Cole, Leukema Research, 3/29/2016
Abstracts/Posters
- Novel Combination of low dose PARP inhibitor (BMN673) and low dose DNMT inhibitor (5-AZA) – A Potential Therapy for Ovarian Cancer?Adeoluwa Adewuyi, Baltimore Areas Repair Symposium, University of Maryland Baltimore, 3/2016
- Novel Combination of low dose PARP inhibitor (BMN673) and low dose DNMT inhibitor (5-AZA) – A Potential Therapy for Ovarian Cancer?Adeoluwa Adewuyi, Graduate Research Conference, University of Maryland Baltimore, 3/2016
- Molecular Diagnosis of Xeroderma PigmentosumAdeoluwa Adewuyi, National Institute of Health (NIH) Summer Research Program, NIH, Bethesda MD, 8/2010
Professional Memberships
- American College of PhysiciansStudent Member
- American Academy of Family PhysiciansStudent Member
- American Society of Biochemistry and Molecular BiologyStudent Member
- Student National Medical AssociationStudent Member
- American College of GastroenterologyStudent Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
